Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides receives USFDA Approval for Flucytosine Capsules
Details : USFDA approved generic version of Flucytosine Capsule (thymidylate synthetase inhibitor) indicated for treating serious infections caused by susceptible strains of Candida and/or Cryptococcus (meningitis and pulmonary infections)
Product Name : Ancobon-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2020
Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anova Begins Phase 1/2a DB107 Trial for High-Grade Gliomas
Details : DB107 is an investigational gene therapy, which is currently being evaluated for the treatment of newly diagnosed high-grade glioma.
Product Name : DB107
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amphotericin B,Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $3.3 million
Deal Type : Private Placement
Matinas BioPharma Acquires Preferred Stock, Appoints Dr. Robin L. Smith
Details : The funds will be used the Company’s antifungal drug candidate MAT2203 (Amphotericin B) for the treatment of invasive fungal infections.
Product Name : MAT2203
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 13, 2025
Lead Product(s) : Amphotericin B,Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $3.3 million
Deal Type : Private Placement
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : California Institute for Regenerative Medicine
Deal Size : $11.8 million
Deal Type : Funding
Cirm Awards $11.8 Million Grant for Trial in High-Grade Glioma Using DB107
Details : The proceeds will advance the development of DB107, consisting of two components: DB107–RRV as a prodrug activator and DB107–FC as an oral prodrug for high-grade glioma, including glioblastoma.
Product Name : DB107
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : California Institute for Regenerative Medicine
Deal Size : $11.8 million
Deal Type : Funding
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DB107 (vocimagene amiretrorepvec) is a two-part cancer-selective immunotherapy comprising an investigational gene therapy treatment and an investigational small molecule, which is investigated for the treatment of newly diagnosed high grade glioma.
Product Name : DB107
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 25, 2023
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TG6002 is novel oncolytic virus that has been engineered to combine multiple mechanisms of action. It has been designed to,selectively replicate within cancer cells. This is due to deletion of viral genes encoding TK and RR.
Product Name : TG6002
Product Type : Microorganism
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : These data provide a clinical proof of concept for Transgene’s double deleted VVcopTK-RR- patented virus backbone: after IV administration, TG6002 reached the tumor, multiplied within tumor cells, and induced the local expression of its payload (the FC...
Product Name : TG6002
Product Type : Microorganism
Upfront Cash : Inapplicable
September 04, 2021
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002
Details : The trial aims at confirming the good tolerability of ascending doses of intravenous TG6002 and at providing the first translational data from this novel route of administration.
Product Name : TG6002
Product Type : Microorganism
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Tianjin Tasly Group
Deal Size : $22.2 million
Deal Type : Financing
Details : Transgene has been a shareholder in Tasly BioPharmaceuticals when it received shares of Tasly Biopharmaceuticals in exchange for the sale of the Greater China rights of T101 and T601, two products respectively incorporating Transgene’s TG6002 and TG105...
Product Name : TG6002
Product Type : Microorganism
Upfront Cash : Undisclosed
April 08, 2020
Lead Product(s) : TG6002,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Tianjin Tasly Group
Deal Size : $22.2 million
Deal Type : Financing
Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Gets USFDA Nod For Flucytosine Capsules
Details : Flucytosine capsules are generic version of Bausch Health's Ancobon capsules. The product will be launched in June 2020.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2020
Lead Product(s) : Fluocytosine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable